IGF-1 LR3

Overview

IGF-1 LR3 (Long Arg³ IGF-1) is a synthetic analog of insulin-like growth factor-1 (IGF-1). It differs from the endogenous protein at two points. First, position 3 carries an arginine instead of a glutamic acid. Second, it has a 13-amino-acid extension at the N-terminus, the 'Long' in the name. Together, those modifications make it an 83-amino-acid protein, against 70 for native IGF-1.

The goal of those modifications is a single property: a strongly reduced affinity for the IGF-binding proteins (IGFBPs), while binding to the IGF-1 receptor is preserved. That matters functionally. Endogenous IGF-1 circulates more than 99% bound to IGFBPs, leaving only a small fraction free and biologically active. IGF-1 LR3 largely bypasses that binding system, which makes it roughly three times more potent than unmodified IGF-1 in cell culture.

A distinction is needed here, and this text holds it strictly. What has been established about IGF-1 LR3 itself in cell and animal models is not the same as what is known about the parent hormone, IGF-1. The broad, well-grounded body of knowledge on IGF-1 signaling concerns endogenous IGF-1; the literature that has examined LR3 itself is preclinical and partly veterinary. The mechanistic basis rests on IGF-1 research, not on LR3 itself. Both are treated separately below.

A second caveat belongs alongside it. IGF-1-receptor signaling is involved in growth, and also in tumor biology: overexpression of the IGF-1 receptor is associated with several tumor types. That argues for a careful, strictly scientific positioning of this compound.

Mechanism of action

IGF-1 LR3 activates the IGF-1 receptor with full potency retained, but binds only weakly to IGFBPs. The net effect is a longer biological availability and more sustained receptor activation than endogenous IGF-1. The mechanisms below are established for IGF-1 signaling; where LR3 itself has been studied, this is indicated.

IGF-1 receptor activation

• Binds the IGF-1 receptor with an affinity comparable to endogenous IGF-1.
• Activates the PI3K/Akt/mTOR pathway, the central regulator of protein synthesis. mTOR is an enzyme complex that directs the assembly of new protein.
• Inhibits the FoxO transcription factors, which in turn drive muscle protein breakdown via the ubiquitin–proteasome system. The ubiquitin–proteasome system is the cell's waste-disposal machinery.

Reduced IGFBP binding

• The Arg³ substitution sharply lowers affinity for the IGFBPs.
• A larger fraction therefore remains free and biologically active than for endogenous IGF-1.
• In several cell models, added IGFBP suppresses LR3-stimulated proliferation, confirming that the reduced binding is at the core of the mechanism.

Effects at cell and tissue level (preclinical)

• In myoblast cultures, LR3 stimulates cell division. Myoblasts are the precursor cells of skeletal muscle.
• In fetal animal models, LR3 stimulates the growth of specific organs, without reliably increasing total body or muscle mass.
• In animal models, LR3 administration lowers the animal's own IGF level and insulin secretion, an indication that it intervenes in the broader hormonal feedback loop.

Research findings

• In cell culture, LR3 is more potent than IGF-1 because it is not sequestered by IGFBPs; this has been repeatedly confirmed in myoblast models.
• In fetal sheep, a one-week infusion increased the growth of heart, spleen, kidneys and adrenals and stimulated myoblast proliferation, but did not increase muscle mass.
• In fetal sheep, an acute infusion suppressed glucose-stimulated insulin secretion; isolated islets recovered the response, indicating a reversible effect.
• In young animals, LR3 is cleared from plasma faster than IGF-1, and oral administration does not lead to absorption.
• In breast cancer cells, LR3 inhibited IGFBP-3-induced apoptosis more strongly than IGF-1. This is a finding in cancer context, not in muscle context.
• There are no human efficacy or safety studies with IGF-1 LR3. The analog has been detected outside research: in doping-control work, LR3 was identified in an illicit injectable preparation, with the explicit statement that human effects have not been studied and that it is most likely a by-product from biochemical research.

LR3-specific findings (cell and animal models)

• In cell culture, LR3 is more potent than IGF-1 because IGFBPs do not sequester it; this has been confirmed repeatedly in myoblast models.
• In fetal sheep, a one-week LR3 infusion increased growth of heart, spleen, kidneys and adrenals and stimulated myoblast proliferation, but did not increase muscle mass.
• In fetal sheep, an acute LR3 infusion suppressed glucose-stimulated insulin secretion; isolated islets recovered the response, indicating a reversible effect.
• In young animals, LR3 is cleared from plasma faster than IGF-1, and oral administration does not produce absorption.
• In breast cancer cells, LR3 blocked IGFBP-3-induced apoptosis more strongly than IGF-1. This is a finding in cancer context, not in muscle context.

IGF-1 mechanistic background (concerns the parent hormone, not LR3 specifically)

• The PI3K/Akt/mTOR pathway and the regulation of protein synthesis are extensively documented for IGF-1.
• IGF-1 activates satellite cells for muscle repair and regeneration.
• IGF-1 suppresses atrophy pathways via inhibition of FoxO.

Human data

• There are no human efficacy or safety studies with IGF-1 LR3.
• The analog has been detected outside research: doping-control work identified LR3 in an illicit injectable preparation, with the explicit observation that human effects have not been studied and that it is more likely a by-product from biochemical research.

Research context

IGF-1 LR3 is scientifically interesting above all as a pharmacological tool: it makes it possible to study IGF-1-receptor signaling without the complication of IGFBP binding. In that role, as a cell-culture reagent and as an infusion in preclinical growth studies, it has been widely used.

The boundary of what is actually known runs sharply along species lines. The LR3-specific literature is real but predominantly animal and fetal in design, often aimed at livestock growth or developmental physiology. The deeper mechanistic knowledge often cited in marketing of this type of compound in reality concerns endogenous IGF-1, not the analog. The mechanistic basis rests on IGF-1 research, not on LR3 itself. Findings about the parent hormone may not simply be transferred to LR3.

In humans there is no efficacy or safety research. That the analog nonetheless appears outside the laboratory, documented in doping-control work, only reinforces the case for a strict research positioning. The IGF-1-receptor pathway is also involved in tumor biology, which is an additional reason for scientific restraint.

Open questions

IGF-1 LR3 is primarily a research reagent. LR3-specific data exists only in cell and animal models; the mechanistic basis rests on the IGF-1 literature. No human efficacy or safety studies have been conducted.

• There are no human efficacy or safety studies with exogenously administered IGF-1 LR3.
• The pharmacokinetic profile after subcutaneous administration in humans has not been characterized.
• The long-term safety profile under repeated use has not been established.
• The role of the IGF-1 receptor in tumor biology calls for careful scientific contextualization.
• Optimal dosing and administration frequency for research purposes have not been standardized.
• Differences between LR3 and endogenous IGF-1 in living tissue have not been fully characterized.

Research outlook

IGF-1 analogs are being investigated for cachexia in chronic disease and for muscle loss in aging.

Controlled-release systems for IGF-1 analogs are an active preclinical research area.

Combination studies with other anabolic pathways are ongoing in muscle biology research.

Selective IGF-1-receptor modulation without systemic side effects remains a research priority.

Scientific interest

IGF-1 receptor signaling and muscle protein synthesis

IGFBP-independent IGF-1 pharmacology

Muscle atrophy and cachexia research

Cell biology and biotechnological research

Specifications

References

1. Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells. · Nickerson T, Huynh H, Pollak M. · Biochemical and Biophysical Research Communications · 1997
2. Hormonal responses and adaptations to resistance exercise and training. · Kraemer WJ, Ratamess NA. · Sports Medicine · 2005
3. Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy. · Yoshida T, Delafontaine P. · Cells · 2020

Availability

Not in catalogue · Profile complete · verification and sourcing not yet finished